Core Viewpoint - Zhongyin International has raised the profit forecast for WuXi AppTec (02359) for 2025 to 2027 by 2.4% to 6.4%, and increased the target price for H-shares from HKD 122 to HKD 127, maintaining a "Buy" rating with a projected P/E ratio of 18 times for next year [1] Financial Performance - WuXi AppTec's Q3 performance exceeded expectations, continuing the strong momentum from the first half of the year, with revenue increasing by 15% year-on-year to RMB 12.1 billion [1] - Net profit rose by 53% year-on-year to approximately RMB 3.5 billion, primarily driven by the ramp-up of late-stage clinical and commercialization projects [1] - Gross margin improved by 7.8 percentage points to 49.8% [1] Order and Growth Outlook - Excluding foreign exchange impacts, new orders for WuXi AppTec increased by 18% year-on-year, with a backlog of orders reaching RMB 60 billion, a 41% year-on-year growth [1] - The company expects to gradually convert this backlog over the next 18 months, supporting visible growth for 2026 [1] - Management has raised the full-year revenue growth guidance to 17% to 18%, up from the previous 13% to 17% [1] Cash Flow and Capital Expenditure - WuXi AppTec's management has adjusted the 2025 free cash flow guidance to RMB 8 billion to 8.5 billion [1] - Capital expenditure has been revised down to RMB 5.5 billion to 6 billion due to project schedule adjustments [1] Global Expansion - The company is steadily advancing its global expansion, with the Singapore API plant expected to be operational by 2027, the U.S. formulation plant projected to start production by the end of 2026, and the expansion of the Swiss base [1] - Management noted that cross-border customer demand remains stable [1]

Core Viewpoint - WuXi AppTec (02359) experienced a significant decline of over 6%, closing at HKD 105.9 with a trading volume of HKD 652 million [1][2]. Group 1: Stock Performance - WuXi AppTec's stock fell by 6.03% as of the latest report, indicating a notable drop in market confidence [1][2]. - The trading volume reached HKD 652 million, reflecting active trading activity despite the decline [2]. Group 2: Shareholder Actions - On October 29, WuXi AppTec announced that its actual controller plans to reduce its holdings in the company due to personal funding needs [2]. - The reduction will occur within three months following the announcement, with a maximum of 2% of the company's total share capital, equating to up to 59,675,143 shares [2].

Core Viewpoint - WuXi AppTec's A-share trading volume reached 10 billion yuan, with a current decline of 8.1% [2] Company Summary - WuXi AppTec's A-share trading volume on October 30 reached 10 billion yuan [2] - The company's stock is currently experiencing a decline of 8.1% [2]

Core Insights - WuXi AppTec's A-share trading volume reached 10 billion yuan, with a current decline of 8.1% [1] Company Summary - WuXi AppTec's A-share trading volume indicates significant market activity, reflecting investor interest [1] - The current decline of 8.1% suggests potential volatility or market correction affecting the company's stock performance [1] Industry Summary - The trading volume of 10 billion yuan positions WuXi AppTec as a notable player in the biotechnology sector, highlighting the industry's liquidity and investor engagement [1]

Core Viewpoint - WuXi AppTec's Q3 performance exceeded expectations, continuing the strong momentum from the first half of the year, with revenue growth of 15% year-on-year to 12.1 billion yuan and net profit growth of 53% year-on-year to approximately 3.5 billion yuan, primarily driven by the ramp-up of late-stage clinical and commercialization projects [1] Financial Performance - Revenue increased by 15% year-on-year to 12.1 billion yuan [1] - Net profit rose by 53% year-on-year to approximately 3.5 billion yuan [1] - Gross margin improved by 7.8 percentage points year-on-year to 49.8% [1] Order Growth - Excluding foreign exchange impacts, new orders increased by 18% year-on-year [1] - The backlog of orders reached 60 billion yuan, a year-on-year growth of 41% [1] - It is expected that the backlog will gradually convert over the next 18 months, supporting visibility for growth through 2026 [1] Management Guidance - Management raised the full-year revenue growth guidance to between 17% and 18%, up from the previous range of 13% to 17% [1] Target Price Adjustment - The target price for H-shares was raised from 122 HKD to 127 HKD, maintaining a forecasted P/E ratio of 18 times for the next year [1] - Earnings forecasts for 2025 to 2027 were increased by 2.4% to 6.4% [1]

Group 1 - WuXi AppTec (02359.HK) experienced a decline of over 6%, specifically a drop of 6.03%, trading at 105.9 HKD [1] - The trading volume reached 652 million HKD [1]

Core Viewpoint - WuXi AppTec (02359) experienced a decline of over 6%, with a current price of HKD 105.9 and a trading volume of HKD 652 million [1] Group 1: Company Announcement - On October 29, WuXi AppTec announced that it received a notice from its actual controller regarding a planned reduction of A-share holdings [1] - The actual controller intends to reduce holdings based on market conditions within three months after the announcement, starting 15 trading days from the disclosure date [1] - The total number of shares to be reduced will not exceed 2% of the company's total share capital, amounting to a maximum of 59,675,143 shares [1]

Investment Rating - The report maintains a "BUY" rating for Pharmaron (3759.HK) since January 1, 2020, with a 12-month price target of HK$30.00, indicating an upside potential of 20.2% from the current price of HK$24.96 [1][12]. Core Insights - Pharmaron reported a 3Q25 revenue of Rmb3.65 billion, reflecting a year-over-year increase of 13.4% and a quarter-over-quarter increase of 9.1%, slightly exceeding Goldman Sachs estimates of Rmb3.48 billion. This growth was driven by strong performance in the CMC and bioscience segments, particularly from the top 20 large pharmaceutical clients [1][2]. - The management has raised the full-year revenue growth guidance to 12-16% year-over-year, up from the previous guidance of 10-15%, suggesting a potential growth of 6-20% year-over-year in 4Q25. The management is optimistic about further margin improvements in 4Q25 compared to the first nine months of 2025 [1][2]. - The report highlights robust new project order momentum, particularly in the CMC segment, where new project orders increased by 13% year-over-year for the first three quarters, with a notable 20% year-over-year rise in CMC new orders driven by large pharmaceutical demand [2][20]. Summary by Sections Earnings Review - 3Q25 revenue: Rmb3.65 billion, up 13.4% y/y and 9.1% q/q, slightly above GSe of Rmb3.48 billion [1]. - Non-IFRS adjusted net profit margin improved to 12.9%, up from 11.3% in 1Q25 and 12.2% in 2Q25, supported by higher utilization rates [1]. Revenue Growth and Guidance - Full-year revenue growth guidance raised to 12-16% y/y from 10-15% y/y, implying 4Q25 growth of 6-20% y/y [1]. - Continued investment in biologics and strategic acquisitions positions Pharmaron for sustained growth in the CDMO space [1][20]. Segment Performance - CMC revenue reached Rmb903 million, up 12.7% y/y and 29.6% q/q, with a gross margin of 34.6% [2]. - Clinical development revenue was Rmb501 million, up 8.2% y/y, but gross margin declined to 10.8% due to project mix and competitive pressures [3][19]. Strategic Acquisitions - The acquisition of Biortus is expected to enhance Pharmaron's biologics service offerings, particularly in structural biology data supporting drug discovery [20]. Financial Projections - Revenue projections for 2025E are Rmb14,066.7 million, with EBITDA of Rmb3,532.9 million and EPS of Rmb0.91 [6][17]. - The report anticipates a 3-year earnings CAGR of 15% [21].

每经AI快讯，10月30日，药明康德跌超6%，股东拟减持不超2%股份。 （文章来源：每日经济新闻） ...

药明康德盘初跌超6%，实际控制人控制的股东计划15个交易日后3个月内减持不超过总股本2%。 ...